Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • Sulfonylureas and meglitinides stimulate insulin release and improve plasma glucose but do not improve insulin resistance and may result in hypoglycemia
  • These agents have not been well studied in patients with HIV and should be reserved as alternate therapeutic options in cases of frank diabetes
  • Sitagliptin may be considered an alternative for patients who do not tolerate other agents or an addition in patients with an inadequate response based on positive results from a small study[Best 2015]

Action required